The Swiss-Italian biotech firm’s two lead assets for cancer are expecting pivotal readouts next year, prompting it to consider partnering strategies and further substantiating its targeted R&D approach.
Philogen S.p.A.’s two lead assets, Nidlegy and Fibromun, are approaching Phase III readouts next year and the firm is mulling its commercialization strategy as its payload-ligand approach to drug development gains traction.
The Swiss-Italian biotech firm was founded in 1996 and has since teamed up with the likes of Janssen Biotech Inc., Novartis AG and Pfizer Inc
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
